Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J C Charniot

Showing results (31-40 of 33) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 33 results.
International Journal of Cardiology|October 30, 2012
Interpretation of lipoprotein-associated phospholipase A2 levels is influenced by cardiac disease, comorbidities, extension of atherosclerosis and treatmentsJ C Charniot, R Khani-Bittar, J P Albertini, et al.
Journal of Medical Genetics|August 16, 2003
Expanding the phenotype of LMNA mutations in dilated cardiomyopathy and functional consequences of these mutationsP Sébillon, C Bouchier, L D Bidot, et al.
Annals of Hematology|January 30, 2013
High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFMC Kelaidi, O Beyne-Rauzy, T Braun, et al.
Pageof 4

Showing results (31-40 of 33) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 33 results.
International Journal of Cardiology|October 30, 2012
Interpretation of lipoprotein-associated phospholipase A2 levels is influenced by cardiac disease, comorbidities, extension of atherosclerosis and treatmentsJ C Charniot, R Khani-Bittar, J P Albertini, et al.
Journal of Medical Genetics|August 16, 2003
Expanding the phenotype of LMNA mutations in dilated cardiomyopathy and functional consequences of these mutationsP Sébillon, C Bouchier, L D Bidot, et al.
Annals of Hematology|January 30, 2013
High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFMC Kelaidi, O Beyne-Rauzy, T Braun, et al.
Pageof 4